Distalmotion Secures $150 Million to Challenge Intuitive in Robotic Surgery Market
Table of Contents
A new contender is emerging in the rapidly evolving field of robotic surgery. Distalmotion, a Swiss medical technology company, announced this week that it has raised $150 million to expand the commercial availability of its Dexter robotic system within the United States.
Distalmotion has already received authorizations from the U.S. Food and Drug Administration to market Dexter for gallbladder, hysterectomy, and hernia repair procedures. The company is strategically targeting the burgeoning ambulatory surgery center (ASC) sector, believing its compact and adaptable robotics platform offers a distinct advantage over the larger, more established systems currently dominating the market.
Dexter’s design for Accessibility
Unlike many existing robotic surgery platforms, Distalmotion’s Dexter is engineered for seamless integration into existing surgical environments. The system’s open architecture allows surgeons to continue utilizing their preferred visualization tools and laparoscopic electrosurgical generators, minimizing disruption and training requirements.
A study published in the Journal of Robotic Surgery in September highlighted the barriers to robotic surgery adoption in ASCs, specifically citing the need for dedicated operating room space, extensive surgeon training, and notable infrastructure investments associated with traditional systems. Researchers concluded these factors limit the potential benefits of minimally invasive robotic procedures for facilities that could most benefit from them.
A $150 Million Bet on the ASC market
With its recent funding, Distalmotion aims to demonstrate that Dexter provides a more practical and cost-effective solution for ASCs. “ASCs represent a tremendous opportunity for Dexter,” stated CEO Greg Roche in a company release, as Distalmotion embarks on the next phase of its U.S. commercialization plan.
This expansion will inevitably position Distalmotion in direct competition with Intuitive, the current leader in soft-tissue robotics with its da Vinci surgical systems. However, intuitive is also recognizing the potential of the ASC market. During a recent earnings call,Intuitive executives discussed a growing trend of hospitals deploying older Xi robots in ASCs after upgrading to the latest da Vinci 5 model.
Cost Remains a Key Obstacle
According to one analyst, the initial capital expenditure remains the primary hurdle to wider robotic adoption in ASCs, outweighing concerns about Medicare coverage or commercial reimbursement rates. Intuitive is addressing this challenge by offering leasing options, reducing the upfront financial burden for facilities.
While the majority of Intuitive systems currently installed in ascs are Xi robots, some facilities utilize the more affordable X platform. Despite the relatively small current footprint of robotic surgery in ASCs, Intuitive executives noted that procedure growth at these sites is “quite a bit accretive” to overall U.S. procedure growth, fueling further interest in the market.
“ASCs are going to be an area of increased interest and focus for us,” a senior official stated. However,they also acknowledged the economic realities,noting that “reimbursement in an ASC is a fraction of the reimbursement in a [hospital outpatient department],” creating a significant barrier,particularly for ASCs affiliated with larger integrated delivery networks.
The competition between Distalmotion and Intuitive is poised to accelerate innovation and possibly lower the cost of robotic surgery, ultimately expandi
